Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Age‐related neurodegenerative diseases such as Alzheimer's disease (AD) are distressing conditions causing countless levels of suffering for which treatment is often insufficient or inexistent. Considered to be the most common cause of dementia and an incurable, progressive neurodegenerative disorder, the intricate pathogenic mechanisms of AD continue to be revealed and, consequently, an effective treatment needs to be developed. Among the diverse hypothesis that have been proposed to explain AD pathogenesis, the one concerning mitochondrial dysfunction has raised as one of the most discussed with an actual acceptance in the field. It posits that manipulating mitochondrial function and understanding the deficits that result in mitochondrial injury may help to control and/or limit the development of AD. To achieve such goal, the concept of mitochondrial medicine places itself as a promising gathering of strategies to directly manage the major insidious disturbances of mitochondrial homeostasis as well as attempts to directly or indirectly manage its consequences in the context of AD. The aim of this review is to summarize the evolution that occurred from the establishment of mitochondrial homeostasis perturbation as masterpieces in AD pathogenesis up until the development of mitochondrial medicine. Following a brief glimpse in the past and current hypothesis regarding the triad of aging, mitochondria and AD, this manuscript will address the major mechanisms currently believed to participate in above mentioned events. Both pharmacological and lifestyle interventions will also be reviewed as AD‐related mitochondrial therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 5×
“Later, in patient post-mortem brain investigation, it was visible the thinning of the cerebral cortex together with two characteristic lesions, neurofibrillary tangles (NFTs) and extracellular deposits that would be later named senile plaques (154).”
BackgroundInfluentialAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“that are in the basis of the “amyloid cascade hypothesis,” came with the identification of familial AD mutations in APP, PS1 and PS2 genes, which have given a big lift to the hypothesis of proteotoxic mechanisms mediated by the oligomers of Ab in explaining the neurodegeneration of the sporadic AD (71, 73).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“Also, nonspecific antioxidants can include melatonin (55), omega-3 polyunsaturated fatty acid (docosahexaenoic acid) (14), curcumin (237), ubiquinone (38) and a-lipoic acid (174).”
BackgroundMitochondria: More Than Just a Powerhouse
McBride, H. M., Neuspiel, M., & Wasiak, S. (2006) · Current Biology · doi:10.1016/j.cub.2006.06.054 · Cited by 1,985 · cited 1×
“Mitochondria play a paramount function in cell survival and death by responding to physiological and environmental signs in order to meet cellular energy and metabolic demands (133).”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“In this setting, evidence from antioxidant-based trials and pre-clinical studies have shed light to the need of concomitant dietary and lifestyle factors in refining efficacy of antioxidant therapies (37, 164).”
BackgroundMitochondrial form and function
Friedman, J. R., & Nunnari, J. (2014) · Nature · doi:10.1038/nature12985 · Cited by 1,803 · cited 1×
“Neurons, that are long, excitable and, highly compartmentalized cells, have an intrinsic dependence in the proper distribution of mitochondria to sustain the spatial and temporal demand of energy that differs within the axons and synapses compared to dendrites and the cell body (58, 81, 114).”
BackgroundThe importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses
Li, Z., Okamoto, K.-I., Hayashi, Y., & Sheng, M. (2004) · Cell · doi:10.1016/j.cell.2004.11.003 · Cited by 1,498
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 3×
“(79), postmortem AD brain tissue possesses decreased number of mitochondria in vulnerable neurons but increased cytosolic accumulation of mitochondrial markers such as mtDNA and subunit I of COX, suggesting an impaired autophagic lysosomal proteolytic degradation, and a possible leak of sequestered material from the a…”
BackgroundInfluentialABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
S-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury
Cho, D.-H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., & Lipton, S. A. (2009) · Science · doi:10.1126/science.1171091 · Cited by 1,092
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081 · cited 1×
“Their role is even more important in neurons that need a large amount of ATP for the synthesis and secretion of neurotransmitters, to enhance the synaptic plasticity and also to maintain the neuronal membrane potential (131).”
BackgroundDishman, R. K., Berthoud, H., Booth, F. W., Cotman, C. W., Edgerton, V. R., Fleshner, M. R., Gandevia, S. C., Gomez‐Pinilla, F., Greenwood, B. N., Hillman, C. H., et al. (2006) · Obesity · doi:10.1038/oby.2006.46 · Cited by 958
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940 · cited 2×
“In this work, mitochondrial impairment in brain tissue from 3xTg-AD was characterized by an increase in hydrogen peroxide production and lipid peroxidation as well by a decrease in mitochondrial respiration, and PDH activity, one of the most important enzyme of oxidative metabolism (239).”
BackgroundWang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., Casadesus, G., & Zhu, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804871105 · Cited by 835
Self-citationThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782 · cited 1×
“SS31, the most extensively studied SS peptide, in particular, is capable of entering mitochondria and of concentrating in the inner mitochondrial membrane, protecting mitochondria against mitochondrial permeability transition pore (mPTP) formation, swelling and cytochrome c release (243).”
BackgroundThe axonal transport of mitochondria
Hollenbeck, P. J., & Saxton, W. M. (2005) · Journal of Cell Science · doi:10.1242/jcs.02745 · Cited by 771
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“Also, new evidence revealed some inconsistencies in the amyloid hypothesis, namely that the amount of Ab deposition in the brain of sporadic AD patients does not always correlate with cognitive impairment and, inversely, Ab deposition can also be found in cognitively normal individuals (32, 78, 144).”
BackgroundA “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“As so, all of those concepts were brought together in the “mitochondrial cascade hypothesis” (209).”
BackgroundAxonal transport deficits and neurodegenerative diseases
Millecamps, S., & Julien, J.-P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3380 · Cited by 755 · cited 1×
“Importantly, studies in 3xTg-AD mice showed that the deficits in axonal transport and axonal swelling precede Ab deposition or filamentous tau aggregation, suggesting that such deficits might be early events in AD (136).”
BackgroundCalorie restriction induces mitochondrial biogenesis and bioenergetic efficiency
López-Lluch, G., Hunt, N., Jones, B., Zhu, M., Jamieson, H., Hilmer, S., Cascajo, M. V., Allard, J., Ingram, D. K., Navas, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510452103 · Cited by 699
Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P. F., Alafuzoff, I., Leinonen, V., Ito, A., Winblad, B., Glaser, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806192105 · Cited by 693
Calkins, M. J., Manczak, M., Mao, P., Shirendeb, U., & Reddy, P. H. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr381 · Cited by 646
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J. T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602909200 · Cited by 626 · cited 1×
“By activating a class of enzymes known as sirtuins, CR posits itself as having remarkable neuroprotective properties (173).”
BackgroundOxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605 · cited 1×
“Likewise, evidence shows that such oxidative stress imbalance directly correlates with severity of cognitive impairment as well as with increasing age (221) and symptomatic progression from MCI to AD (10).”
BackgroundCytochrome oxidase deficiency in Alzheimer’s disease
Parker, W. D., Filley, C. M., & Parks, J. K. (1990) · Neurology · doi:10.1212/wnl.40.8.1302 · Cited by 598
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · cited 2×
“Knowing that APP processing is a highly regulated event directly affected by bioenergetics metabolism and, having in mind the previous assumption that with advancing age mitochondrial function changes, investigators hypothesized that the accumulation of Ab could be a consequence of mitochondria damage during aging rat…”
BackgroundEvidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease
Marcus, D. L., Thomas, C., Rodriguez, C., Simberkoff, K., Tsai, J. S., Strafaci, J. A., & Freedman, M. L. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6750 · Cited by 513 · cited 1×
“As described, ROSmediated injury, mainly through increased levels of lipid peroxidation markers, namely thiobarbituric acid reactive substances and 4hydroxynonenal, is found in the brains of AD patients compared to controls (21, 123) Noteworthy, a previous study elegantly demonstrated that mitochondria-derived ROS the…”
Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
Neuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · cited 5×
“Later, in patient post-mortem brain investigation, it was visible the thinning of the cerebral cortex together with two characteristic lesions, neurofibrillary tangles (NFTs) and extracellular deposits that would be later named senile plaques (154).”
BackgroundInfluentialMcManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., Shirendeb, U. P., Calkins, M. J., Reddy, A. P., Mao, P., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.011 · Cited by 394 · cited 1×
“In turn, this elevation of free radicals activates fission proteins Drp1 and Fis1 and causes excessive mitochondrial fragmentation, defective transport of mitochondria to synapses, low synaptic ATP levels and synaptic dysfunction in AD neurons (177).”
BackgroundPharmacological approaches to restore mitochondrial function
Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383 · cited 1×
“As mentioned before, mitochondrial dysfunction, especially a defect in mitochondrial biogenesis, is an early and prominent feature of AD (172), so it seems that compounds and/or interventions that reverse the PGC1a deficit, or otherwise enhance PGC1a activity or expression, constitutes a feasible AD therapeutic target…”
BackgroundCataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., & Nixon, R. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90324-0 · Cited by 379
Neurodegenerative lysosomal disorders: A continuum from development to late age
Nixon, R. A., Yang, D.-S., & Lee, J.-H. (2008) · Autophagy · doi:10.4161/auto.6259 · Cited by 362
Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation
Leuner, K., Schütt, T., Kurz, C., Eckert, S. H., Schiller, C., Occhipinti, A., Mai, S., Jendrach, M., Eckert, G. P., Kruse, S. E., et al. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4173 · Cited by 354
Bosetti, F. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00314-1 · Cited by 348
Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease
Resende, R., Moreira, P. I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C., & Oliveira, C. R. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.012 · Cited by 343
Self-citationDiet and risk of dementia: Does fat matter?: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2002) · Neurology · doi:10.1212/01.wnl.0000038345.77753.46 · Cited by 324
Brain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease
Atamna, H., & Frey, W. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.06.001 · Cited by 278
Velliquette, R. A., O'Connor, T., & Vassar, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2350-05.2005 · Cited by 254
Cunnane, S. C., Courchesne‐Loyer, A., St‐Pierre, V., Vandenberghe, C., Pierotti, T., Fortier, M., Croteau, E., & Castellano, C. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12999 · Cited by 250
Butterfield, D. A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C., & Sultana, R. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.017 · Cited by 246 · cited 1×
“As demonstrated, MCI subjects often present increased levels of oxidative stress markers and decreased levels of non-enzymatic antioxidants (22, 94, 170, 180).”
BackgroundVenkateshappa, C., Harish, G., Mahadevan, A., Srinivas Bharath, M. M., & Shankar, S. K. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0755-8 · Cited by 232 · cited 1×
“Likewise, evidence shows that such oxidative stress imbalance directly correlates with severity of cognitive impairment as well as with increasing age (221) and symptomatic progression from MCI to AD (10).”
BackgroundMitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230 · cited 1×
“As the main source of energy for the normal function of brain cells, the decline of mitochondria function has been proposed to be a major factor in the loss of brain function with aging and in age-related neurodegenerative disorders (176).”
BackgroundRapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Ding, Q., Vaynman, S., Souda, P., Whitelegge, J. P., & Gomez‐Pinilla, F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05026.x · Cited by 174
Yao, J., Chen, S., Mao, Z., Cadenas, E., & Brinton, R. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021788 · Cited by 169
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment
Valla, J., Schneider, L., Niedzielko, T., Coon, K. D., Caselli, R., Sabbagh, M. N., Ahern, G. L., Baxter, L., Alexander, G., Walker, D. G., et al. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.10.004 · Cited by 159
Carvalho, C., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.001 · Cited by 145
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Roy, N., Hutfles, L., Burns, J. M., Michaelis, E. K., Yan, S., Cardoso, S. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt247 · Cited by 133 · cited 8×
“Using the well-known cybrid Brain Pathology 26 (2016) 632–647 VC 2016 International Society of Neuropathology 635 cell model, which lacks their own mtDNA and in which exogenous mtDNA from control, AD and MCI patients were introduced, it was found that AD cybrid cells had significant changes in morphology and function,…”
InfluentialSelf-citationExpression of β-Amyloid Induced Age-Dependent Presynaptic and Axonal Changes in Drosophila
Zhao, X.-L., Wang, W.-A., Tan, J.-X., Huang, J.-K., Zhang, X., Zhang, B.-Z., Wang, Y.-H., YangCheng, H.-Y., Zhu, H.-L., Sun, X.-J., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3699-09.2010 · Cited by 130 · cited 1×
“Likewise, Ab overexpression in Drosophila decreased mitochondrial velocity in both directions, which is associated with axonal depletion of mitochondria (244).”
BackgroundDoes exercise reduce brain oxidative stress? A systematic review
Camiletti‐Moirón, D., Aparicio, V. A., Aranda, P., & Radak, Z. (2013) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/sms.12065 · Cited by 104 · cited 1×
“Among those, are included an increased content and/or activity of several enzymes involved in aerobic energy production (48, 49, 96), increased activity of mitochondrial complexes I, III and IV (147), decreased expression/activation of several pro-apoptotic proteins (217), increased mitochondrial biogenesis (201) and…”
BackgroundDevelopment of Mitochondria‐targeted Aromatic‐cationic Peptides for Neurodegenerative Diseases
Szeto, H. H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.013 · Cited by 100 · cited 2×
“By having a sequence motif that allows them to target mitochondria, even in depolarized mitochondria, these SS peptides display mitochondrial accumulation and ability to scavenge H2O2 and inhibit lipid peroxidation (210).”
BackgroundPark, J., Choi, H., Min, J., Kim, B., Lee, S., Yun, J. W., Choi, M., Chang, K., & Lee, D. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12984 · Cited by 93
Folwell, J., Cowan, C. M., Ubhi, K. K., Shiabh, H., Newman, T. A., Shepherd, D., & Mudher, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.014 · Cited by 83
Masitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80 · cited 1×
“Despite that, most of the investigational drugs available targeting APP and Ab have consistently failed (56).”
Background
Cited by
Perez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426
Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration
Andersen, J. V., Markussen, K. H., Jakobsen, E., Schousboe, A., Waagepetersen, H. S., Rosenberg, P. A., & Aldana, B. I. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108719 · Cited by 371
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Andersen, J. V., Skotte, N. H., Christensen, S. K., Polli, F. S., Shabani, M., Markussen, K. H., Haukedal, H., Westi, E. W., Diaz-delCastillo, M., Sun, R. C., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04237-y · Cited by 104
Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential
Mi, Y., Qi, G., Brinton, R. D., & Yin, F. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8070 · Cited by 43
“It is thus not surprising that of the complex and progressive AD phenotypes, glucose hypometabolism and impaired mitochondrial bioenergetics are among the earliest events before clinical diagnosis (25).”
Background
Metadata
- Authors
- Cardoso, S., Carvalho, C., Correia, S. C., Seiça, R. M., & Moreira, P. I.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2016-09
- Volume
- 26
- Issue
- 5
- Pages
- 632-647
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2469323302
- Cited by
- 67
- References
- 63
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.